FUJIFILM Holdings Corporation

Business Description

Four segments carry the group. Healthcare, roughly a third of revenue, spans medical imaging — X-ray systems, endoscopes, ultrasound — and Bio CDMO, the contract development and manufacture of biologic drugs for other pharmaceutical companies. Business Innovation, the largest at about 35%, is the office-equipment arm once run as the Fuji Xerox joint venture; Fujifilm bought out Xerox's stake in 2019 and renamed it, so it now sells worldwide under its own name. Imaging, around 19%, still sells cameras — the instax instant-print line and the X-series mirrorless system. Electronics, some 14%, supplies photoresists, CMP slurries and cleaning chemicals to chipmakers.

The pivot is the story an investor needs. When digital cameras destroyed film demand in the 2000s, the company redeployed the science underneath it — collagen, antioxidants, thin-film coating, fine-particle engineering — into healthcare and advanced materials, while Eastman Kodak, its principal global rival in film, ended up in bankruptcy protection. Earnings now turn on two engines: Bio CDMO, where very heavy capacity investment in Denmark, the United States and the United Kingdom has to be filled with orders to pay off, and semiconductor materials, which ride the chip cycle and draw directly on the film-coating heritage. instax remains an unexpectedly strong performer in a business most people assume is dead. About 65% of revenue comes from outside Japan, so the yen is a direct swing factor. Incorporated in 1934, it reports on a March fiscal year.

Corporate Data

Latest Coverage

• August 6, 2026 Fujifilm Q1 Operating Profit Falls 32% as Bio-CDMO Fixed Costs Push Healthcare to a ¥12.7 Billion Loss
• May 19, 2026 Fujifilm FY26 Operating Income Hits Record ¥350bn as AI Semi Materials and Imaging Offset Healthcare Weakness